AEON Biopharma, Inc.: change in accounts payable

What this measure means

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Exact concept: us-gaap:IncreaseDecreaseInAccountsPayable. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2022-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• AEON Biopharma, Inc.: total assets
• AEON Biopharma, Inc.: total liabilities
• AEON Biopharma, Inc.: stockholders equity
• AEON Biopharma, Inc.: cash and cash equivalents
• AEON Biopharma, Inc.: net income or loss
• AEON Biopharma, Inc.: operating cash flow
• AEON Biopharma, Inc.: financing cash flow
• AEON Biopharma, Inc.: investing cash flow
• AEON Biopharma, Inc.: retained earnings or deficit
• AEON Biopharma, Inc.: basic weighted-average shares
• AEON Biopharma, Inc.: diluted weighted-average shares
• AEON Biopharma, Inc.: basic earnings per share
• AEON Biopharma, Inc.: diluted earnings per share
• AEON Biopharma, Inc.: net property, plant and equipment
• AEON Biopharma, Inc.: share-based compensation expense
• AEON Biopharma, Inc.: operating income or loss
• AEON Biopharma, Inc.: current assets
• AEON Biopharma, Inc.: current liabilities
• AEON Biopharma, Inc.: current accounts payable
• AEON Biopharma, Inc.: operating expenses
• AEON Biopharma, Inc.: selling, general and administrative expense
• AEON Biopharma, Inc.: research and development expense
• AEON Biopharma, Inc.: common shares outstanding
• AEON Biopharma, Inc.: cash including restricted cash
• AEON Biopharma, Inc.: additional paid-in capital
• AEON Biopharma, Inc.: total equity including noncontrolling interests
• AEON Biopharma, Inc.: operating lease right-of-use asset
• AEON Biopharma, Inc.: operating lease liability
• AEON Biopharma, Inc.: gross property, plant and equipment
• AEON Biopharma, Inc.: accumulated depreciation on property, plant and equipment
• AEON Biopharma, Inc.: other noncurrent assets
• AEON Biopharma, Inc.: prepaid expenses and other current assets
• AEON Biopharma, Inc.: net deferred tax assets
• AEON Biopharma, Inc.: pre-tax income or loss from continuing operations
• AEON Biopharma, Inc.: profit or loss including noncontrolling interests
• AEON Biopharma, Inc.: net income available to common stockholders
• AEON Biopharma, Inc.: depreciation, depletion and amortization
• AEON Biopharma, Inc.: other nonoperating income or expense
• AEON Biopharma, Inc.: nonoperating income or expense
• AEON Biopharma, Inc.: operating lease payments

Inspect the source

Entity

AEON Biopharma, Inc. / CIK 0001837607

Captured

2026-09-21T17:29:50.996Z

SEC response SHA-256

976029d82f5d8e8df46acac5fd0f8f0502e669de4260fc049cc4fa8c20c63230

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001837607.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))